• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»surgical navigation

Why DePuy Synthes’ Gemtrack deal could reshape navigation in hip, knee and shoulder surgery

By Pallavi Madhiraju on May 27, 2026   Medical Devices & Diagnostics  

Why DePuy Synthes’ Gemtrack deal could reshape navigation in hip, knee and shoulder surgery

DePuy Synthes wants to remove a robotics bottleneck. Its Gemtrack deal could change joint surgery navigation if regulators agree.

Medtronic broadens Stealth AXiS reach as integrated surgical platforms gain strategic importance

By Pallavi Madhiraju on March 28, 2026   Medical Devices & Diagnostics  

Medtronic broadens Stealth AXiS reach as integrated surgical platforms gain strategic importance

Medtronic won FDA clearance for Stealth AXiS in cranial and ENT surgery. Read why this platform move could reshape surgical workflow competition.

Recent Posts

  • Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?
  • GlycoNex targets Prolia and Xgeva space as SPD8 meets Phase III equivalence goal
  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes